Organogenesis Holdings (FRA:2PQ) Valuation Rank


FRA:2PQ Organogenesis Holdings Inc FRA:2PQ
66 GF Score
Price €2.06
GF Value €2.71
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Organogenesis Holdings Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Organogenesis Holdings Valuation Rank Related Terms

FRA:2PQ
66GF Score
Organogenesis Holdings Inc FRA:2PQ
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Organogenesis Holdings (FRA:2PQ) Overvalued in 2026?

Based on GuruFocus' analysis, Organogenesis Holdings stock appears to be undervalued. The current stock price of €2.06 is trading 24% below its estimated GF Value™ of €2.71. GuruFocus considers Organogenesis Holdings to be Modestly Undervalued.

Key valuation signals for FRA:2PQ:

  • Valuation Rank:
  • GF Value™: €2.71 vs. price of €2.06 (24% below fair value)
  • GF Score™: 66/100 with 5 warning signs

No single metric tells the full story. See the FRA:2PQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Organogenesis Holdings Business Description

Other Exchanges ORGO:USA
Address 85 Dan Road, Canton, MA, USA, 02021
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
66GF Score

Get the complete analysis for FRA:2PQ

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.06
Price
€2.71
GF Value